MOTS-c Peptide: Benefits, Side Effects, and What the Evidence Shows

01The Short Answer

What Is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA, and your body makes it on its own in response to metabolic stress such as exercise. Its full name is mitochondrial open reading frame of the 12S rRNA type-c, which describes exactly where it comes from: a short stretch of code inside the 12S ribosomal RNA gene in the mitochondrial genome.

That origin is the interesting part. Mitochondria were treated for decades as passive power plants. MOTS-c is evidence they also send messages, because the peptide is translated in the cytosol and then acts on the rest of the body, including the cell nucleus.

• MOTS-c is a natural peptide, not a synthetic drug invented in a lab
• Its documented sequence is MRWQEMGYIFYPRKLR, 16 amino acids long
• Exercise raises MOTS-c levels in human skeletal muscle and blood
• Circulating MOTS-c declines with age and in metabolic dysfunction
• It is not approved by the FDA for any medical use

So MOTS-c is best understood as a signal your mitochondria already send, which researchers are now studying as a possible therapy.

02Mechanism

How Does MOTS-c Work in the Body?

MOTS-c works in the body mainly by activating AMPK, the enzyme cells use as a low-fuel alarm, which pushes skeletal muscle toward burning glucose and fat rather than storing them. The 2015 paper that identified the peptide showed the route it takes to get there: MOTS-c inhibits the folate cycle and the purine synthesis tethered to it, and the metabolites that build up as a result switch AMPK on.

AMPK is worth naming because you have probably met it before. Metformin, the most-prescribed drug in type 2 diabetes, also works through AMPK. The overlap is not trivial, and the Alzheimer's Drug Discovery Foundation review of MOTS-c flags it as a reason the peptide could interact with other AMPK-targeting medicines.

The two differ in where they act. Metformin acts primarily on the liver. MOTS-c appears to act primarily on skeletal muscle, which is also the tissue that releases it during exercise.

MOTS-c therefore works less like a stimulant and more like a message telling muscle to behave the way it behaves when you train.

03Benefits

What Are the Benefits of MOTS-c Seen in Research?

The benefits of MOTS-c seen in research are metabolic, and they come almost entirely from cells and mice rather than people. In the original Cell Metabolism study, MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity.

The second strand of evidence is physical performance. A 2021 Nature Communications paper reported that MOTS-c significantly enhanced physical performance in young, middle-aged and old mice, and that treatment started late in life, at 23.5 months, still raised physical capacity. The same paper is the source of the most widely repeated human finding on this topic: exercise induces endogenous MOTS-c expression in human skeletal muscle and in circulation.

That human finding is often misquoted. It shows that exercise raises the MOTS-c your own body makes. It does not show that injecting MOTS-c reproduces exercise.

The research benefits of MOTS-c are real as findings and preliminary as evidence, which is a distinction worth holding onto.

04FDA Status

Is MOTS-c Approved by the FDA?

MOTS-c is not approved by the FDA for any medical use, and no MOTS-c product is an approved drug. There is no FDA-approved indication, no approved label and no approved manufacturer for it.

Compounded peptide preparations are not FDA-approved either. The FDA does not review a compounded preparation for safety, effectiveness or quality before a patient uses it, which is a different regulatory position from an approved medicine and should be understood before starting one. Our guide to whether peptides are legal covers the compounding rules and the research-use grey market in more detail.

The FDA has looked specifically at MOTS-c as a compounding ingredient and said it has found no human exposure data for any route of administration, and that compounded MOTS-c may pose a significant risk of immunogenicity. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 7 to 5 to recommend adding MOTS-c to the list of substances compounding pharmacies may use, over FDA staff objection. That recommendation is not binding and the FDA has not acted on it.

Much of what is sold online as MOTS-c is labeled for research use only, which is a legal category for laboratory material rather than a quality guarantee for something injected into a person.

The regulatory answer is unambiguous: MOTS-c is not FDA-approved, and anything prescribed is prescribed outside an approval.

05Human Evidence

Has MOTS-c Been Tested in Humans?

MOTS-c has been tested in humans exactly once, in a trial that is still enrolling and has reported nothing, and that is the most important thing on this page. The Alzheimer's Drug Discovery Foundation review, last updated in September 2025, records the peptide's availability as research use and its dose as not established.

The first clinical trial of MOTS-c itself began in February 2026. NCT07505745 is a Phase 2a randomized, double-blind, placebo-controlled study in 120 adults with prediabetes and overweight or obesity, run by Hudson Biotech, with primary completion estimated for February 2027. It is still recruiting and has reported nothing, so it cannot yet tell you whether MOTS-c works.

An earlier human trial comes close and is routinely cited as though it were MOTS-c itself. It was not. The trial, NCT03998514, tested CB4211, an analog of MOTS-c developed by CohBar, in a Phase 1a single and multiple ascending dose study in healthy adults, followed by a Phase 1b in subjects with obesity and fatty liver disease. Eighty-eight subjects took part across the program.

Its history is instructive. The Phase 1a study was temporarily suspended in 2018 because of persistent mild injection-site reactions, described as painless bumps that may reflect some of the compound remaining at the injection site. It resumed under an amended protocol and completed in 2019, and the Phase 1b completed in 2021 with topline results reporting that the analog met its primary safety endpoint with no serious adverse events. Full safety data were not disclosed.

So the honest state of human evidence is one completed Phase 1 program, in 88 people, on a different molecule, reported partly by press release, plus one Phase 2 trial of the peptide itself that has not reported. Human evidence for MOTS-c is pending rather than positive.

06Side Effects

What Are the Side Effects of MOTS-c?

The side effects of MOTS-c are not formally established, because no controlled trial has ever measured them for the peptide itself. That is a gap in the evidence rather than a clean safety record, and the two are easy to confuse.

What exists is two weaker sources. The analog CB4211 produced persistent injection-site reactions often enough to pause its own Phase 1 study. Separately, the US Anti-Doping Agency reports that self-experimenters have described increased heart rate or palpitations, injection-site irritation, insomnia, local or generalized immune reactions and fever, which is anecdote rather than trial data and should be read as such.

• Injection-site reactions, the one effect documented in a registered trial of the analog
• Palpitations or raised heart rate, reported by self-experimenters and not measured in a trial
• Insomnia, fever and local or generalized immune reactions, from the same anecdotal reports
• Possible interaction with other AMPK-acting medicines such as metformin
• Unknown long-term safety, with no human data at all beyond the analog

The ADDF review adds one caution worth repeating: it has not been established whether there is a level of MOTS-c, or a set of conditions, under which the peptide becomes maladaptive rather than helpful.

Treat the side effects of MOTS-c as unknown rather than absent, and treat that uncertainty as the main reason the decision belongs with a prescriber.

07Sex Differences

Does MOTS-c Work Differently in Men and Women?

MOTS-c appears to work differently in men and women, and this is one of the better-evidenced findings on the topic. A 2021 study in Aging examined an Asian-specific mitochondrial variant that changes one amino acid in MOTS-c and found, across a meta-analysis of three cohorts totaling 27,527 people, that males but not females carrying the variant had a higher prevalence of type 2 diabetes.

The animal arm of the same paper pointed the same way. High-fat-fed male mice injected with MOTS-c showed reduced weight and improved glucose tolerance, while female mice were unaffected.

The explanation researchers favor is hormonal. Circulating MOTS-c is more affected by metabolic dysfunction in males than in pre-menopausal females, which is thought to reflect the influence of ovarian hormones including estrogen.

Men and women may therefore not respond to MOTS-c equally, and the honest position is that the sex difference is documented while its clinical meaning is not yet settled.

08Sport

Is MOTS-c Banned in Sport?

MOTS-c is banned in sport by the World Anti-Doping Agency, and the US Anti-Doping Agency publishes guidance on it for exactly that reason. Any athlete subject to anti-doping testing should treat MOTS-c as prohibited.

The ban is a useful signal even for people who never compete. Agencies prohibit substances they consider performance-altering, which tells you regulators take the mechanism seriously, and they prohibit substances whose long-term safety is unestablished, which tells you the evidence gap is recognized outside medicine too.

If you are tested in any sanctioned sport, MOTS-c is not an option, whatever a clinic or a seller tells you.

09The Physician's View

What Most MOTS-c Pages Leave Out

Most MOTS-c pages leave out the fact that should frame the whole decision: there is no established human dose for MOTS-c, because no completed human trial has established one. The Alzheimer's Drug Discovery Foundation's review of MOTS-c lists the dose as not established in its own summary table, while commercial pages selling it publish dosing sections anyway.

That is why this page has no dosage chart and no calculator. A table of numbers for an unapproved peptide implies a validated regimen behind it, and there is not one. Any schedule circulating online traces back to someone's preference or to an animal study, not to a dose-finding trial in people.

The second omission is the direction of causation. Exercise raises your own MOTS-c. That is the finding. It does not follow that raising MOTS-c produces the effects of exercise, and the mouse data showing performance gains were produced by injecting a peptide into animals, not by watching people get fitter.

The third is magnitude. The preclinical metabolic effects of MOTS-c are proportional to how dysfunctional the metabolism already is, so young healthy animals showed only marginal improvements while aged and overweight animals showed the dramatic ones. The people most drawn to a performance peptide are often the ones least likely to have the headroom the mouse data depended on.

The useful question about MOTS-c is therefore not what dose to take, but whether a peptide with no human efficacy data belongs in your plan before the things that do have it.

10The Protocol Health Approach

MOTS-c at Protocol Health

Protocol Health lists MOTS-c under its peptide therapy services, and a provider decides whether it belongs in your plan after reviewing your goals, health history, symptoms and relevant testing. The treatment page for MOTS-c at Protocol Health states that the format is vial peptide therapy, that compounded peptide preparations are not FDA-approved, and that your provider explains the regulatory status of any peptide before prescribing it. That is the whole of what the clinic publishes about this peptide, and nothing beyond it is claimed here.

Protocol Health offers peptide therapy commercially, so we have a financial interest in the category this article discusses. That is precisely why the evidence limits above are stated at full strength rather than in a footnote. Care is delivered in person at the Scarsdale clinic and by telehealth, and our guide to peptide therapy in NYC explains how prescribing and compounding work in New York. To start, take the Protocol Health quiz.

If what you are actually after is metabolic and physical durability over decades, the groundwork matters more than the molecule, and our guide to healthspan versus lifespan covers what the evidence supports there.

This article is educational and is not medical advice. MOTS-c is not approved by the FDA for any use, and whether it is appropriate for you is a question for a consultation with a prescriber who can see your full history.

FAQ

Frequently Asked Questions

Explore

Related at Protocol Health

• MOTS-c →
• Peptide Therapy →
• Are Peptides Legal? →
• Peptide Therapy in NYC →